SanPharma Immune-Metabolic Therapy
For many years, immune modulation therapy has been used to help patients fight acute and chronic illnesses. Primary goals of this therapy are to 1) enhance overall immunological reactivity in case of suppression and 2) balance an overactive, excessive immune response to restore healthy normal function.

Scientific articles published in peer-reviewed journals demonstrated that the effects of a modern lifestyle have significantly impacted the human immune system, making it more sensitive than in the past. As a result, SanPharma of Dohren, Germany has taken a new approach to immune system modulation that has become increasingly popular: use of microbial therapy derived from highly dilute metabolic products of fungi and bacteria. The remedies are manufactured at a Good Manufacturing Practices (GMP)-certified facility in Germany, and registered with the FDA for sale in the U.S.
 
Supported by Scientific Research
A breakthrough scientific study has shown conclusively that the SanPharma immune-metabolic fungal remedies work to fight infections by activating natural killer (NK) cells. The study was conducted by Natural Immune Systems Inc. in Klamath Falls, Oregon, a private contract research lab specializing in assessment of the effects of natural products on the human immune system.

According to chief immunologist and project director Dr. Gitte Jensen, the highly dilute fungal metabolites specifically activated human CD3-CD56+NK cells in vitro, as shown by the induction of the CD69 marker on up to 50% of NK cells after 18 hours culture with metabolites. Study results showed that SanPharma medications did not cause inflammatory reactions, such as induction of COX-2 enzymes.

Additional key advantages of treating patients with SanPharma remedies include:

1. Contain no cell wall antigenic material found in other so-called isopathic remedies to eliminate the potential for inflammatory reactions.
2. Constant training and modulation of the immune system
3. Work on the gut-associated lymphoid tissue (GALT), and activate macrophages and natural killer cells that internalize toxins.

Founded in the mid-1970s, SanPharma is owned and directed by Gerhard and Edelgard Schroeder. For nearly 22 years, the company produced isopathic remedies derived from dilutions of cell wall fragments, similar to those marketed by other companies. These preparations were sold by SanPharma primarily in Scandinavia, as well as in Germany through partnership with a pharmacy.